Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 04 Jan 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Acronyms Complete-AS
- Sponsors Abbott Laboratories; AbbVie
- 28 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Jul 2017 Planned number of patients changed from 1120 to 915.
- 13 Jul 2017 Planned End Date changed from 1 Jun 2018 to 30 Nov 2019.